mastocytosis
Conditions
Brief summary
The primary endpoint of this study is the change of mast cell activation symptoms as pruritus and/or flushes between the start of treatment and 12 months later.
Detailed description
- The difference on mast cell mass between the start of treatment and 12 months later, The difference of other mast cell activation symptoms such as diarrhea, pollakiuria, arthralgia and discomfort between the start of treatment and 12 months later., Tolerance by clinical examination and if necessary paraclinical according to the investigator's decision; tolerance will be assessed during the study period, The correlation of the effectiveness of treatment with the hydroxychloroquine and level of serum HCQ
Interventions
DRUGPLAQUENIL 200 mg
DRUGcomprimé pelliculé
Sponsors
Centre Hospitalier Universitaire De Toulouse
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint of this study is the change of mast cell activation symptoms as pruritus and/or flushes between the start of treatment and 12 months later. | — |
Secondary
| Measure | Time frame |
|---|---|
| - The difference on mast cell mass between the start of treatment and 12 months later, The difference of other mast cell activation symptoms such as diarrhea, pollakiuria, arthralgia and discomfort between the start of treatment and 12 months later., Tolerance by clinical examination and if necessary paraclinical according to the investigator's decision; tolerance will be assessed during the study period, The correlation of the effectiveness of treatment with the hydroxychloroquine and level of serum HCQ | — |
Countries
France
Outcome results
None listed